CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company is headquartered in Largo, Florida.
| Revenue (TTM) | $1.37B |
| Gross Profit (TTM) | $762.31M |
| EBITDA | $227.46M |
| Operating Margin | 14.60% |
| Return on Equity | 5.53% |
| Return on Assets | 4.14% |
| Revenue/Share (TTM) | $44.70 |
| Book Value | $34.73 |
| Price-to-Book | 1.33 |
| Price-to-Sales (TTM) | 1.02 |
| EV/Revenue | 1.588 |
| EV/EBITDA | 11.56 |
| Quarterly Earnings Growth (YoY) | 11.20% |
| Quarterly Revenue Growth (YoY) | 0.30% |
| Shares Outstanding | $29.95M |
| Float | $29.66M |
| % Insiders | 0.43% |
| % Institutions | 116.48% |
Volatility is currently expanding
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CNMD and any ticker you trade — then tracks every position and per-strategy win rate.
